Announcement PDF radiopharmaceutical company developing Therapeutic and Imaging products using peptides, small molecules, nanobodies and antibodies. Annual General Meeting 25 November 2024 Company Presentation Radiopharm Theranostics (ASX “RAD”) is a clinical stage Notice & Disclaimer The information in this presentation does not constitute personal investment advice. The presentation is not intended to be comprehensive or provide all information required by investors to make an informed decision on any investment in Radiopharm Theranostics Ltd ACN 647 877 889 (Company). In preparing this presentation, the Company did not take into account the investment objectives, financial situation and particular needs of any particular investor. Further advice should be obtained from a professional investment adviser before taking any action on any information dealt with in the presentation. Those acting upon any information without advice do so entirely at their own risk. Whilst this presentation is based on information from sources which are considered reliable, no representation or warranty, express or implied, is made or given by or on behalf of the Company, any of its directors, or any other person about the accuracy, completeness or fairness of the information or opinions contained in this presentation. No responsibility or liability is accepted by any of them for that information or those opinions or for any errors, omissions, misstatements (negligent or otherwise) or for any communication written or otherwise, contained or referred to in this presentation. Neither the Company nor any of its directors, officers, employees, advisers, associated persons or subsidiaries are liable for any direct, indirect or consequential loss or damage suffered by any person as a result of relying upon any statement in this presentation or any document supplied with this presentation, or by any future communications in connection with those documents and all of those losses and damages are expressly disclaimed. Certain statements contained in this presentation, including, without limitation, statements containing the words “believes,” “plans,” “expects,” “anticipates,” and words of similar import, constitute “forward-looking statements.” Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors include, among others, the following: the risk that our clinical trials will be delayed and not completed on a timely basis; the risk that the results from the clinical trials are not as favourable as we anticipate; the risk that our clinical trials will be more costly than anticipated; and the risk that applicable regulatory authorities may ask for additional data, information or studies to be completed or provided prior to their approval of our products. Given these uncertainties, undue reliance should not be placed on such forward-looking statements. The Company disclaims any obligation to update any such factors or to publicly announce the results of any revisions to any of the forward-looking statements contained herein to reflect future events or developments except as required by law. This presentation is not a prospectus or other disclosure document under the Corporations Act 2001 (Cth) and will not be lodged with the Australian Securities and Investments Commission. This presentation is for information purposes only and is not an invitation or offer of securities for subscription, purchase or sale in any jurisdiction. The distribution of this presentation (including electronically) outside Australia may be restricted by law. If you come into possession of this presentation, you should observe such restrictions as any non-compliance with these restrictions could contravene applicable securities laws (see the section captioned ‘International offer restrictions’). In particular, this document does not constitute an offer to sell, or a solicitation of an offer to buy, securities in the United States. The New Shares have not been, and will not be, registered under the US Securities Act of 1933 and may not be offered or sold in the United States except in transactions exempt from, or not subject to, the registration requirements of the US Securities Act and applicable US state securities laws. Any opinions expressed reflect the Company’s position at the date of this presentation and are subject to change. 2 INVESTMENT HIGHLIGHTS 3 Innovative clinical stage molecules Highly differentiated Imaging agent (Pivalate) for Brain Mets - large disease area with high unmet needPotential first-in-class PD-L1 targeting radiopharmaceutical Potential best-in-class HER2 targeting radiopharmaceutical 3 Highly promising late stage-preclinical molecules Potential first-in-class B7H3 (from Joint Venture / Strategic partnership with MD Anderson) Potential first-in-class KLK3 targeting radiopharmaceutical Theranostic Pair targeting Integrin AvB6, with Imaging Phase I proof of concept ongoing Solid financials Strong investment endorsement from Lantheus with ~7% ; Institutional Shareholders own 64% Cash runway to mid-2026 3 COMPANY PIPELINE PROGRAM TARGET & MOLECULE INDICATION Dx/Tx ISOTOPE PRECLINICAL PHASE I PHASE II NOTES Clinical RAD 101 Short Chain Fatty Acid Phase 2a RAD202 IND approval received for Phase 2b in US (n=30) BRAIN METS Imaging F18 PD-L1 NON-SMALL CELL LUNG CANCER Therapy Lu177 Phase 1 enrolling in Australia, NCT06305962 HREC approval to expansion in multiple tumors First two cohorts’ patients’ data by mid-2025 HER 2 BREAST / GASTRIC CANCER Therapy Lu177 Ethics approval for Phase 1 expected by Dec 2024 First two cohorts’ patients’ data by the end of 2025 (Small molecule) RAD204 Phase 2b (Nanobody) (Nanobody) FPFV expected in Dec 2024 Pre-Clinical RV01 B7H3 RAD402 RAD 301/302 (mAb) Therapy Lu177 KLK3 PROSTATE Therapy Tb161 Multiple Solid Tumors Therapy Lu177 Phase 1 Therapeutic planned for end of 2025 Imaging Ga68 Phase 1 Imaging enrolling in USA (mAb) Integrin αVβ6 (peptide) 4 IND approval expected mid-2025 Multiple Solid Tumors FPFV Phase 1 in Q3 2025 Ethics approval in Q3 2025 FPFV Phase 1 in Q4 2025 Targeting MoA: SHORT FATTY ACID CHAINS Imaging for BRAIN METASTASIS Molecule: RAD 101 UPCOMING MILESTONES PROGRAM RAD101 TARGET & MOLECULE Short Chain Fatty Acid INDICATION BRAIN METS Dx/Tx Imaging ISOTOPE F18 1ST HALF 2024 2ND HALF 2024 IND Approval Phase 2b received (Small Molecule) 1ST HALF 2025 2ND HALF 2025 10/30 patients’ data to be released Phase 2 Top Line data First Patient Ph 2b ACHIEVED Future Milestone 6 1ST HALF 2026 Targeting MoA: PDL1 Therapeutic for NON-SMALL CELL LUNG CANCER 7 Molecule: RAD 204 RAD 204 – UPCOMING MILESTONES PROGRAM RAD204 TARGET & MOLECULE PD-L1 (Nanobody) INDICATION NON-SMALL CELL LUNG CANCER Dx/Tx Therapy ISOTOPE Lu177 1ST HALF 2024 2ND HALF 2024 Ethics Approval received First Patient treated at Wollongong Hospital Nepean Hospital opened 1ST HALF 2025 2ND HALF 2025 2 Cohorts completed & data release Phase 1 Top Line data ACHIEVED Future Milestone 8 1ST HALF 2026 Targeting MoA: HER2 Therapeutic for BREAST AND GASTRIC CANCER 9 Molecule: RAD 202 RAD 202 – UPCOMING MILESTONES PROGRAM RAD202 TARGET & MOLECULE HER2 (Nanobody) INDICATION BREAST & GASTRIC Dx/Tx Therapy ISOTOPE Lu177 1ST HALF 2024 2ND HALF 2024 Ethics Submission 1ST HALF 2025 First Patient dosed Ethics Approval ACHIEVED Future Milestone 10 2ND HALF 2025 1ST HALF 2026 2 Cohorts completed & data release Phase 1 Top Line data CORPORATE SNAPSHOT Shareholders: 64% Institutions + 10% Board Stock Code: RAD 12-month trading range: AUD$0.023(Oct24) – AUD$0.137(Oct 23) 13% Market Cap: AUD$52m 31% Shares on Issue: 2.17 billion Options on Issue: 850m @ 6c / 2y Cash at Bank: AUD$43M No. of Shareholders: 2,300 13% 10% 11% 11 22% Autralian Institutions US Institutions Corporate Holders Board & Management Retail Brokers & Banks Top 20 Shareholders 2024, Oct 29th JP Morgan (incl. Point72) 175.096.000 Deutsche Bank 157.420.000 Lantheus 149.625.000 Paul Hopper 149.221.000 Regal Funds 142.140.000 Octagon 93.703.000 OC Funds 88.500.000 Investors Mutual 75.000.000 Australian Ethical 57.633.000 Silverarc 56.221.888 Northstar 51.234.000 Affinity 46.851.574 Dellora 46.851.574 UBS Securities 44.182.000 NanoMab 43.295.000 Atlantis Fund 42.356.000 Thorney 40.502.000 Merril Lynch 31.459.000 Goldman Sachs 24.044.000 Scarlett Hopper 23.857.000 Contacts 12 Riccardo Canevari Paul Hopper CEO & Managing Director Executive Chairman T +1 862 309 0293 T +61 406 671 515 E rc@radiopharmtheranostic.com E paulhopper@lifescienceportfolio.com W www.radiopharmtheranostics.com W www.radiopharmtheranostics.com